PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP | Zendy

Arian Nachat | Zendy; Sam Turoff-Ortmeyer | Zendy; Chunnan Liu | Zendy; Michael McCulloch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP

Author(s) -

Arian Nachat,

Sam Turoff-Ortmeyer,

Chunnan Liu,

Michael McCulloch

Publication year - 2016

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/15-153

Subject(s) - prolymphocytic leukemia , medicine , vincristine , rituximab , alemtuzumab , leukemia , chronic lymphocytic leukemia , chop , transplantation , immunology , cancer research , oncology , chemotherapy , cyclophosphamide , lymphoma

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive leukemia distinct from chronic lymphocytic leukemia, with median survival of only 3 years. B-PLL is resistant to most chemotherapy and newer targeted therapies such as alemtuzumab and thalidomide. Phenylethyl isothiocyanate (PEITC) is a natural compound from horseradish with evidence for therapeutic potential in multiple leukemia types.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research